---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-047119"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:18:25.172688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q3 net loss $52.5M; BMS collaboration provides $110M upfront

## Summary
- Net loss of $52.5M in Q3 2024 vs. $50.7M in Q3 2023; R&D expenses $40.3M, G&A $14.1M.
- Pro-forma cash $244.6M, sufficient to fund operations into 1H 2026.
- Entered strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies; $110M upfront (including $55M equity investment), potential milestones >$3.5B.
- Wilson's Disease program initiated IND-enabling activities; IND/CTA filing expected 1H 2026.
- Phase 1/2 trial of PM359 for p47 phox CGD ongoing; initial clinical data expected in 2025.

## SEC filing metadata
- accession: 0001628280-24-047119
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828024047119/0001628280-24-047119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828024047119/prme-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-047119
- JSON: https://secwatch.observer/filing/0001628280-24-047119.json
- Plain text: https://secwatch.observer/filing/0001628280-24-047119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.